GlaxoSmithKline (GSK) Rating Lowered to Equal Weight at Barclays
Barclays cut shares of GlaxoSmithKline (NYSE:GSK) from an overweight rating to an equal weight rating in a research report sent to investors on Tuesday, Marketbeat Ratings reports. They currently have $36.95 price target on the pharmaceutical company’s stock.
Other analysts have also issued reports about the stock. TheStreet upgraded shares of GlaxoSmithKline from a c rating to a b rating in a research report on Monday, August 6th. Wolfe Research assumed coverage on shares of GlaxoSmithKline in a research report on Tuesday, October 23rd. They set a market perform rating for the company. JPMorgan Chase & Co. restated a neutral rating on shares of GlaxoSmithKline in a research report on Tuesday, September 25th. Zacks Investment Research lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research report on Tuesday, November 27th. Finally, Liberum Capital lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research report on Thursday, August 30th. Thirteen equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $41.79.
Shares of NYSE GSK opened at $37.30 on Tuesday. The company has a debt-to-equity ratio of 6.66, a current ratio of 0.95 and a quick ratio of 0.63. The company has a market cap of $92.80 billion, a P/E ratio of 12.47, a price-to-earnings-growth ratio of 2.51 and a beta of 0.81. GlaxoSmithKline has a 12-month low of $34.83 and a 12-month high of $42.36.
The company also recently declared a quarterly dividend, which will be paid on Thursday, January 10th. Shareholders of record on Friday, November 16th will be given a $0.486 dividend. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.46. This represents a $1.94 dividend on an annualized basis and a dividend yield of 5.21%. The ex-dividend date of this dividend is Thursday, November 15th. GlaxoSmithKline’s dividend payout ratio is presently 67.36%.
Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its holdings in shares of GlaxoSmithKline by 1,788.6% in the third quarter. Bank of New York Mellon Corp now owns 2,306,091 shares of the pharmaceutical company’s stock worth $92,636,000 after buying an additional 2,183,983 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of GlaxoSmithKline by 15.0% in the second quarter. Renaissance Technologies LLC now owns 9,329,400 shares of the pharmaceutical company’s stock worth $376,068,000 after buying an additional 1,216,600 shares in the last quarter. Eaton Vance Management lifted its holdings in shares of GlaxoSmithKline by 49.3% in the third quarter. Eaton Vance Management now owns 1,916,771 shares of the pharmaceutical company’s stock worth $76,996,000 after buying an additional 633,093 shares in the last quarter. Morgan Stanley lifted its holdings in shares of GlaxoSmithKline by 16.5% in the third quarter. Morgan Stanley now owns 4,212,892 shares of the pharmaceutical company’s stock worth $169,232,000 after buying an additional 597,367 shares in the last quarter. Finally, South Texas Money Management Ltd. purchased a new position in shares of GlaxoSmithKline in the second quarter worth $22,195,000. Institutional investors and hedge funds own 10.97% of the company’s stock.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Can systematic risk be avoided?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.